Free Trial

Sarepta Therapeutics (SRPT) Competitors

+3.13 (+1.95%)
(As of 06/24/2024 ET)


Should you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), Takeda Pharmaceutical (TAK), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "pharmaceutical preparations" industry.

Sarepta Therapeutics vs.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Sarepta Therapeutics (NASDAQ:SRPT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations.

In the previous week, Sarepta Therapeutics had 34 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 49 mentions for Sarepta Therapeutics and 15 mentions for Jazz Pharmaceuticals. Jazz Pharmaceuticals' average media sentiment score of 0.62 beat Sarepta Therapeutics' score of 0.33 indicating that Sarepta Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jazz Pharmaceuticals
6 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Sarepta Therapeutics
14 Very Positive mention(s)
10 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)

Jazz Pharmaceuticals has a net margin of 8.61% compared to Jazz Pharmaceuticals' net margin of 1.20%. Sarepta Therapeutics' return on equity of 27.86% beat Jazz Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals8.61% 27.86% 8.91%
Sarepta Therapeutics 1.20%2.20%0.58%

Sarepta Therapeutics received 336 more outperform votes than Jazz Pharmaceuticals when rated by MarketBeat users. However, 80.60% of users gave Jazz Pharmaceuticals an outperform vote while only 75.39% of users gave Sarepta Therapeutics an outperform vote.

Jazz PharmaceuticalsOutperform Votes
Underperform Votes
Sarepta TherapeuticsOutperform Votes
Underperform Votes

Jazz Pharmaceuticals has higher revenue and earnings than Sarepta Therapeutics. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$3.83B1.81$414.83M$4.8522.65
Sarepta Therapeutics$1.24B12.46-$535.98M$0.111,489.55

Jazz Pharmaceuticals presently has a consensus price target of $190.00, indicating a potential upside of 72.99%. Sarepta Therapeutics has a consensus price target of $184.83, indicating a potential upside of 12.81%. Given Sarepta Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Sarepta Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
Sarepta Therapeutics
0 Sell rating(s)
3 Hold rating(s)
15 Buy rating(s)
0 Strong Buy rating(s)

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 4.2% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 7.7% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Jazz Pharmaceuticals has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Sarepta Therapeutics has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.


Jazz Pharmaceuticals beats Sarepta Therapeutics on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SRPT vs. The Competition

MetricSarepta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$15.49B$7.02B$5.09B$8.40B
Dividend YieldN/A2.74%5.25%4.10%
P/E Ratio1,489.5512.13128.1914.69
Price / Sales12.46266.852,347.7969.31
Price / CashN/A32.2633.0830.59
Price / Book17.835.554.724.22
Net Income-$535.98M$146.29M$108.14M$215.61M
7 Day Performance39.42%1.32%0.27%0.09%
1 Month Performance32.72%-1.61%-3.08%-2.47%
1 Year Performance43.61%-7.21%-2.93%0.21%

Sarepta Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
Jazz Pharmaceuticals
4.877 of 5 stars
-12.0%$6.81B$3.84B22.652,800Positive News
Ionis Pharmaceuticals
4.2853 of 5 stars
+12.7%$6.52B$788M-16.73927News Coverage
Positive News
Gap Up
High Trading Volume
Mirati Therapeutics
0.149 of 5 stars
N/A$4.12B$12.44M-4.80587Analyst Forecast
Ultragenyx Pharmaceutical
4.4138 of 5 stars
-21.5%$3.28B$434.25M-4.911,276Analyst Revision
Takeda Pharmaceutical
1.167 of 5 stars
-19.1%$40.76B$28.20B23.4249,095Gap Down
Alnylam Pharmaceuticals
3.6246 of 5 stars
+15.7%$28.19B$1.83B-83.172,100Analyst Forecast
News Coverage
Gap Up
High Trading Volume
Teva Pharmaceutical Industries
0.7147 of 5 stars
+116.3%$18.67B$15.85B-40.2137,851Insider Selling
News Coverage
Genmab A/S
3.342 of 5 stars
Royalty Pharma
4.8923 of 5 stars
-12.4%$16.20B$2.36B20.2351Positive News
BioMarin Pharmaceutical
4.8465 of 5 stars
-8.9%$16.17B$2.42B79.573,401Positive News

Related Companies and Tools

This page (NASDAQ:SRPT) was last updated on 6/25/2024 by Staff

From Our Partners